dedifferentiated liposarcoma(English)

• historically, systemic therapy options in soft tissue sarcomas have been limited to cytotoxic chemotherapy agents. Recently, clinical benefit of the cytotoxic agents trabectedin and eribulin along with the tyrosine kinase inhibitor pazopanib has been established, in addition to highly amplified expression of MDM2 and CDK4); aka DDL
• LPS, RPL, DDL, WDL
• Oncology, Therapeutic approaches
• https://doi.org…1864-020-0705-7